Loading…
Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine
Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papa...
Saved in:
| Published in: | International journal of cardiology 2020-09, Vol.314, p.1-6 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3 |
| container_end_page | 6 |
| container_issue | |
| container_start_page | 1 |
| container_title | International journal of cardiology |
| container_volume | 314 |
| creator | Matsumoto, Hidenari Mikuri, Mikiko Masaki, Ryota Tanaka, Hideaki Ogura, Kunihiro Arai, Taitou Sakai, Rikuo Oishi, Yosuke Okada, Natsumi Shinke, Toshiro |
| description | Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention.
FFRs were measured using nicorandil 2 mg (FFRNC2), nicorandil 4 mg (FFRNC4), and papaverine (FFRPAP) in 40 patients (group 1), and using nicorandil 2 mg, ATP (FFRATP), ATP plus nicorandil (FFRATP+NC2), and papaverine in 20 patients with (group 2) and in 20 patients without caffeine abstention (group 3).
In group 1, FFRNC2 and FFRNC4 did not differ (p = 0.321) and were higher than FFRPAP (p |
| doi_str_mv | 10.1016/j.ijcard.2020.05.013 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2401110284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0167527320300978</els_id><sourcerecordid>2401110284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3</originalsourceid><addsrcrecordid>eNp9kc1u1DAUhS0EokPhDRDykk1S_8YZFkhoRKFSJTawtjz2Db2jxA52MtU8Ba9cV1NYsGBlS_7OOff6EPKWs5Yz3l0dWjx4l0MrmGAt0y3j8hnZ8N6ohhutnpNNxUyjhZEX5FUpB8aY2m77l-RCCtkbocWG_L4GV3CPIy4nmgaKccnOp5yiyycasV5dDDjSIeX6GFaP8Se9O82QYUJHU6RDFSxYBRUa0z3NUCAfgU7Vea0UxOUD3aVpdhlL5e9xufsnZ3azO0LGCK_Ji8GNBd48nZfkx_Xn77uvze23Lze7T7eNl51YGsWc34feQN-ZIJmT3WCkAwMB5KA7tuc8eK0rI7eK6eCCDE4Fr7re68EHeUnen33nnH6tUBY7YfEwji5CWosVinHOmehVRdUZ9TmVkmGwc8apjm05s49V2IM9V2Efq7BM21pFlb17Slj3E4S_oj9_X4GPZwDqnkeEbItHiB4CZvCLDQn_n_AA2xqhww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2401110284</pqid></control><display><type>article</type><title>Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Matsumoto, Hidenari ; Mikuri, Mikiko ; Masaki, Ryota ; Tanaka, Hideaki ; Ogura, Kunihiro ; Arai, Taitou ; Sakai, Rikuo ; Oishi, Yosuke ; Okada, Natsumi ; Shinke, Toshiro</creator><creatorcontrib>Matsumoto, Hidenari ; Mikuri, Mikiko ; Masaki, Ryota ; Tanaka, Hideaki ; Ogura, Kunihiro ; Arai, Taitou ; Sakai, Rikuo ; Oishi, Yosuke ; Okada, Natsumi ; Shinke, Toshiro</creatorcontrib><description>Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention.
FFRs were measured using nicorandil 2 mg (FFRNC2), nicorandil 4 mg (FFRNC4), and papaverine (FFRPAP) in 40 patients (group 1), and using nicorandil 2 mg, ATP (FFRATP), ATP plus nicorandil (FFRATP+NC2), and papaverine in 20 patients with (group 2) and in 20 patients without caffeine abstention (group 3).
In group 1, FFRNC2 and FFRNC4 did not differ (p = 0.321) and were higher than FFRPAP (p < 0.001 and p = 0.0026). Likewise, FFRNC2 was higher than FFRPAP in groups 2 (p = 0.049) and 3 (p < 0.010). In the whole group, Bland-Altman analysis showed a modest mean difference (0.015, p < 0.001) and narrow 95% limits of agreement (−0.025 and 0.056). FFRNC2 and FFRPAP strongly correlated (r = 0.975, p < 0.001). Compared with FFRPAP, FFRATP and FFRATP+NC2 did not differ in group 2 (p = 1.0 and p = 0.780), but they were higher (p = 0.002 and p = 0.02) in group 3. Adjunctive nicorandil did not decline FFR further in groups 2 (p = 0.942) and 3 (p = 0.294).
Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. Increasing the nicorandil dose to 4 mg or administering adjunctive nicorandil during ATP infusions does not offer any clinical advantages compared with administering nicorandil 2 mg alone.
•FFRnicorandil highly correlated with FFRpapaverine independent of serum caffeine, with a modest overestimation.•Increasing the nicorandil dose to 4 mg was not associated with a greater decline in fractional flow reserve.•Adjunctive nicorandil during ATP infusions did not completely overcome the caffeine antagonism.•Nicorandil 2 mg can be a safe and practical alternative for patients who consume caffeine before the test.</description><identifier>ISSN: 0167-5273</identifier><identifier>EISSN: 1874-1754</identifier><identifier>DOI: 10.1016/j.ijcard.2020.05.013</identifier><identifier>PMID: 32387252</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Coronary Angiography ; Coronary Circulation ; Coronary hyperemia ; Coronary Stenosis ; Feasibility Studies ; Fractional flow reserve ; Fractional Flow Reserve, Myocardial ; Humans ; Hyperemia - chemically induced ; Nicorandil ; Papaverine - pharmacology ; Vasodilator Agents - pharmacology</subject><ispartof>International journal of cardiology, 2020-09, Vol.314, p.1-6</ispartof><rights>2020 Elsevier B.V.</rights><rights>Copyright © 2020 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3</citedby><cites>FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32387252$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Matsumoto, Hidenari</creatorcontrib><creatorcontrib>Mikuri, Mikiko</creatorcontrib><creatorcontrib>Masaki, Ryota</creatorcontrib><creatorcontrib>Tanaka, Hideaki</creatorcontrib><creatorcontrib>Ogura, Kunihiro</creatorcontrib><creatorcontrib>Arai, Taitou</creatorcontrib><creatorcontrib>Sakai, Rikuo</creatorcontrib><creatorcontrib>Oishi, Yosuke</creatorcontrib><creatorcontrib>Okada, Natsumi</creatorcontrib><creatorcontrib>Shinke, Toshiro</creatorcontrib><title>Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine</title><title>International journal of cardiology</title><addtitle>Int J Cardiol</addtitle><description>Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention.
FFRs were measured using nicorandil 2 mg (FFRNC2), nicorandil 4 mg (FFRNC4), and papaverine (FFRPAP) in 40 patients (group 1), and using nicorandil 2 mg, ATP (FFRATP), ATP plus nicorandil (FFRATP+NC2), and papaverine in 20 patients with (group 2) and in 20 patients without caffeine abstention (group 3).
In group 1, FFRNC2 and FFRNC4 did not differ (p = 0.321) and were higher than FFRPAP (p < 0.001 and p = 0.0026). Likewise, FFRNC2 was higher than FFRPAP in groups 2 (p = 0.049) and 3 (p < 0.010). In the whole group, Bland-Altman analysis showed a modest mean difference (0.015, p < 0.001) and narrow 95% limits of agreement (−0.025 and 0.056). FFRNC2 and FFRPAP strongly correlated (r = 0.975, p < 0.001). Compared with FFRPAP, FFRATP and FFRATP+NC2 did not differ in group 2 (p = 1.0 and p = 0.780), but they were higher (p = 0.002 and p = 0.02) in group 3. Adjunctive nicorandil did not decline FFR further in groups 2 (p = 0.942) and 3 (p = 0.294).
Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. Increasing the nicorandil dose to 4 mg or administering adjunctive nicorandil during ATP infusions does not offer any clinical advantages compared with administering nicorandil 2 mg alone.
•FFRnicorandil highly correlated with FFRpapaverine independent of serum caffeine, with a modest overestimation.•Increasing the nicorandil dose to 4 mg was not associated with a greater decline in fractional flow reserve.•Adjunctive nicorandil during ATP infusions did not completely overcome the caffeine antagonism.•Nicorandil 2 mg can be a safe and practical alternative for patients who consume caffeine before the test.</description><subject>Coronary Angiography</subject><subject>Coronary Circulation</subject><subject>Coronary hyperemia</subject><subject>Coronary Stenosis</subject><subject>Feasibility Studies</subject><subject>Fractional flow reserve</subject><subject>Fractional Flow Reserve, Myocardial</subject><subject>Humans</subject><subject>Hyperemia - chemically induced</subject><subject>Nicorandil</subject><subject>Papaverine - pharmacology</subject><subject>Vasodilator Agents - pharmacology</subject><issn>0167-5273</issn><issn>1874-1754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kc1u1DAUhS0EokPhDRDykk1S_8YZFkhoRKFSJTawtjz2Db2jxA52MtU8Ba9cV1NYsGBlS_7OOff6EPKWs5Yz3l0dWjx4l0MrmGAt0y3j8hnZ8N6ohhutnpNNxUyjhZEX5FUpB8aY2m77l-RCCtkbocWG_L4GV3CPIy4nmgaKccnOp5yiyycasV5dDDjSIeX6GFaP8Se9O82QYUJHU6RDFSxYBRUa0z3NUCAfgU7Vea0UxOUD3aVpdhlL5e9xufsnZ3azO0LGCK_Ji8GNBd48nZfkx_Xn77uvze23Lze7T7eNl51YGsWc34feQN-ZIJmT3WCkAwMB5KA7tuc8eK0rI7eK6eCCDE4Fr7re68EHeUnen33nnH6tUBY7YfEwji5CWosVinHOmehVRdUZ9TmVkmGwc8apjm05s49V2IM9V2Efq7BM21pFlb17Slj3E4S_oj9_X4GPZwDqnkeEbItHiB4CZvCLDQn_n_AA2xqhww</recordid><startdate>20200901</startdate><enddate>20200901</enddate><creator>Matsumoto, Hidenari</creator><creator>Mikuri, Mikiko</creator><creator>Masaki, Ryota</creator><creator>Tanaka, Hideaki</creator><creator>Ogura, Kunihiro</creator><creator>Arai, Taitou</creator><creator>Sakai, Rikuo</creator><creator>Oishi, Yosuke</creator><creator>Okada, Natsumi</creator><creator>Shinke, Toshiro</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200901</creationdate><title>Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine</title><author>Matsumoto, Hidenari ; Mikuri, Mikiko ; Masaki, Ryota ; Tanaka, Hideaki ; Ogura, Kunihiro ; Arai, Taitou ; Sakai, Rikuo ; Oishi, Yosuke ; Okada, Natsumi ; Shinke, Toshiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Coronary Angiography</topic><topic>Coronary Circulation</topic><topic>Coronary hyperemia</topic><topic>Coronary Stenosis</topic><topic>Feasibility Studies</topic><topic>Fractional flow reserve</topic><topic>Fractional Flow Reserve, Myocardial</topic><topic>Humans</topic><topic>Hyperemia - chemically induced</topic><topic>Nicorandil</topic><topic>Papaverine - pharmacology</topic><topic>Vasodilator Agents - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Matsumoto, Hidenari</creatorcontrib><creatorcontrib>Mikuri, Mikiko</creatorcontrib><creatorcontrib>Masaki, Ryota</creatorcontrib><creatorcontrib>Tanaka, Hideaki</creatorcontrib><creatorcontrib>Ogura, Kunihiro</creatorcontrib><creatorcontrib>Arai, Taitou</creatorcontrib><creatorcontrib>Sakai, Rikuo</creatorcontrib><creatorcontrib>Oishi, Yosuke</creatorcontrib><creatorcontrib>Okada, Natsumi</creatorcontrib><creatorcontrib>Shinke, Toshiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Matsumoto, Hidenari</au><au>Mikuri, Mikiko</au><au>Masaki, Ryota</au><au>Tanaka, Hideaki</au><au>Ogura, Kunihiro</au><au>Arai, Taitou</au><au>Sakai, Rikuo</au><au>Oishi, Yosuke</au><au>Okada, Natsumi</au><au>Shinke, Toshiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine</atitle><jtitle>International journal of cardiology</jtitle><addtitle>Int J Cardiol</addtitle><date>2020-09-01</date><risdate>2020</risdate><volume>314</volume><spage>1</spage><epage>6</epage><pages>1-6</pages><issn>0167-5273</issn><eissn>1874-1754</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Adenosine and adenosine triphosphate (ATP) are widely used to induce hyperemia for fractional flow reserve (FFR) measurements. Caffeine attenuates their hyperemic effects, but not those of nicorandil and papaverine. No studies have systematically compared the hyperemic efficacies of nicorandil, papaverine, and ATP with and without caffeine abstention.
FFRs were measured using nicorandil 2 mg (FFRNC2), nicorandil 4 mg (FFRNC4), and papaverine (FFRPAP) in 40 patients (group 1), and using nicorandil 2 mg, ATP (FFRATP), ATP plus nicorandil (FFRATP+NC2), and papaverine in 20 patients with (group 2) and in 20 patients without caffeine abstention (group 3).
In group 1, FFRNC2 and FFRNC4 did not differ (p = 0.321) and were higher than FFRPAP (p < 0.001 and p = 0.0026). Likewise, FFRNC2 was higher than FFRPAP in groups 2 (p = 0.049) and 3 (p < 0.010). In the whole group, Bland-Altman analysis showed a modest mean difference (0.015, p < 0.001) and narrow 95% limits of agreement (−0.025 and 0.056). FFRNC2 and FFRPAP strongly correlated (r = 0.975, p < 0.001). Compared with FFRPAP, FFRATP and FFRATP+NC2 did not differ in group 2 (p = 1.0 and p = 0.780), but they were higher (p = 0.002 and p = 0.02) in group 3. Adjunctive nicorandil did not decline FFR further in groups 2 (p = 0.942) and 3 (p = 0.294).
Nicorandil 2 mg is a safe and practical alternative for patients who consume caffeine-containing products before the test or have contraindications for adenosine/ATP. Increasing the nicorandil dose to 4 mg or administering adjunctive nicorandil during ATP infusions does not offer any clinical advantages compared with administering nicorandil 2 mg alone.
•FFRnicorandil highly correlated with FFRpapaverine independent of serum caffeine, with a modest overestimation.•Increasing the nicorandil dose to 4 mg was not associated with a greater decline in fractional flow reserve.•Adjunctive nicorandil during ATP infusions did not completely overcome the caffeine antagonism.•Nicorandil 2 mg can be a safe and practical alternative for patients who consume caffeine before the test.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>32387252</pmid><doi>10.1016/j.ijcard.2020.05.013</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-5273 |
| ispartof | International journal of cardiology, 2020-09, Vol.314, p.1-6 |
| issn | 0167-5273 1874-1754 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2401110284 |
| source | ScienceDirect Freedom Collection 2022-2024 |
| subjects | Coronary Angiography Coronary Circulation Coronary hyperemia Coronary Stenosis Feasibility Studies Fractional flow reserve Fractional Flow Reserve, Myocardial Humans Hyperemia - chemically induced Nicorandil Papaverine - pharmacology Vasodilator Agents - pharmacology |
| title | Feasibility of intracoronary nicorandil for inducing hyperemia on fractional flow reserve measurement: Comparison with intracoronary papaverine |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T08%3A34%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20intracoronary%20nicorandil%20for%20inducing%20hyperemia%20on%20fractional%20flow%20reserve%20measurement:%20Comparison%20with%20intracoronary%20papaverine&rft.jtitle=International%20journal%20of%20cardiology&rft.au=Matsumoto,%20Hidenari&rft.date=2020-09-01&rft.volume=314&rft.spage=1&rft.epage=6&rft.pages=1-6&rft.issn=0167-5273&rft.eissn=1874-1754&rft_id=info:doi/10.1016/j.ijcard.2020.05.013&rft_dat=%3Cproquest_cross%3E2401110284%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c362t-40acbd87e867d30a36f73ae7ede3f560b11dc55cbd39405dad3da4dc468c5fcd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2401110284&rft_id=info:pmid/32387252&rfr_iscdi=true |